

Special Issue

Gene Delivery and Gene Editing

Message from the Guest Editor

While gene delivery and editing technologies have become commonplace due to the prevalence of highly advanced methods, it is essential to recognize that ongoing development is imperative. The ultimate role of genetic engineers is to acquire a flawless technology that can, in a specific and efficient manner, revert mutated or defective genes to their healthy wild-type form without any side effects. In this Special Issue, we aim to compile reviews addressing the current status, challenges, and issues related to gene editing, gene delivery technologies, and peripheral technologies in drug development, diagnostics, and medicine. We also expect comprehensive articles that present new insights from diverse perspectives. We are particularly interested in exploring the potential of new functional modules for CRISPR-Cas, proteins beyond typical Cas proteins, advancements in TALEN, the discovery and characterization of unknown type I or II transposons and viruses, and the medical applications stemming from these discoveries.

- gene delivery
- gene editing
- novel module
- transposon
- genetic engineering

Guest Editor

Dr. Kosuke Ishikawa

Japan Biological Informatics Consortium (JBIC), 2-4-32 Aomi, Koto-ku, Tokyo 135-8073, Japan

Deadline for manuscript submissions

closed (31 March 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/192901

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).